Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome

Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome....

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2020-09, Vol.346, p.577308-577308, Article 577308
Main Authors: Garcia-Estrada, Christian, Casallas-Vanegas, Adriana, Zabala-Angeles, Indhira, Gomez-Figueroa, Enrique, Rivas-Alonso, Verónica, Flores-Rivera, José
Format: Article
Language:English
Subjects:
Myelitis
Neuro-Behçet
Pseudotumoral lesion
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult. We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient. [Display omitted]
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2020.577308